Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle  
11/26/14Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015-- ALISO VIEJO, Calif., Nov. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for AVP-825. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally... 
 Printer Friendly Version
11/20/14Avanir Pharmaceuticals to Participate in Two Conferences in December
ALISO VIEJO, Calif., Nov. 20, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in December. Deutsche Bank 2014 BioFEST Presentation date: Tuesday, December 2, 2014 Presentation time: 11:05 a.m. E.T. Piper Jaffray 26th Annual Healthcare Conference Presentation date: Wednesday, December 3, 2014 Presentation time: 9:30 a.m. E.T. ... 
 Printer Friendly Version
11/07/14Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued preliminary written feedback to its New Drug Application (NDA) for AVP-825. AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human factor validation study data submitted a... 
 Printer Friendly Version
10/30/14Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"
ALISO VIEJO, Calif., Oct. 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating the efficacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder (22mg) delivered intranasally utilizing a novel Breath Powered™ delivery technology, for the acute... 
 Printer Friendly Version
10/13/14Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting
--Study Demonstrated Clinically Meaningful and Statistically Significant Improvement of Agitation in Patients with Alzheimer's Disease-- ALISO VIEJO, Calif., Oct. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting. In this study utilizing the two-stage, sequential... 
 Printer Friendly Version
10/08/14Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
- Meeting and Webcast to Begin at 7:30 a.m. Eastern Time - ALISO VIEJO, Calif., Oct. 8, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients... 
 Printer Friendly Version
10/08/14Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease
ALISO VIEJO, Calif., Oct. 8, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA) Annual Meeti... 
 Printer Friendly Version
09/29/14Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
ALISO VIEJO, Calif., Sept. 29, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the closing of its previously announced public offering of 20,930,000 shares of its common stock, including 2,730,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch acted as joint book-running m... 
 Printer Friendly Version
09/23/14Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., Sept. 23, 2014 /PRNewswire/ --Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the pricing of a public offering of 18,200,000 shares of its common stock in an underwritten public offering at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch are acting as joint book-running managers for the offering. Piper Jaffray and JMP Securities are acting as co-managers for the offering. Avani... 
 Printer Friendly Version
09/22/14Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock
ALISO VIEJO, Calif., Sept. 22, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it is offering to sell $200 million of its common stock in an underwritten public offering.  J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch are acting as joint book-running managers for the offering.  Avanir intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are being sold ... 
 Printer Friendly Version
09/15/14Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease
- Significantly Improved Agitation in 220-Patient 10-week Study - - Company Plans to Meet with FDA to Discuss Initiation of Pivotal Development Program - - Data to be Presented at the American Neurological Association Meeting in October - ALISO VIEJO, Calif., Sept. 15, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients... 
 Printer Friendly Version
09/02/14Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
ALISO VIEJO, Calif., Sept. 2, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Morgan Stanley Global Healthcare Conference in New York. Presentation date: Tuesday September 9, 2014 Presentation time: 5:15 p.m. ET A live webcast and 30-day archive of this presentation will be available at http://ir.avanir.com. About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is... 
 Printer Friendly Version
08/26/14Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
--Study to Utilize Sequential Parallel Comparison Design to Minimize Placebo Response, Same Design Utilized in AVP-923 Phase II Study in Agitation in Alzheimer's Disease-- ALISO VIEJO, Calif., Aug. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient into a phase II study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). AVP-786 is a novel investiga... 
 Printer Friendly Version
08/05/14Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights Total company net revenues of $28.6 million. Net NUEDEXTA® sales of $26.5 million. Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with the positive outcome ... 
 Printer Friendly Version
08/05/14Avanir Pharmaceuticals to Participate in Two Conferences in August
ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in August. Wedbush Life Sciences Conference Presentation date: Tuesday August 12, 2014 Presentation time: 9:45 a.m. ET Canaccord Genuity Annual Growth Conference Presentation date: Wednesday, August 13, 2014 Presentation time: 3:00 p.m. ET A live... 
 Printer Friendly Version
07/28/14Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference Call
ALISO VIEJO, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended June 30, 2014 after market close on Tuesday, August 5, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day. Conference Call Information: Domestic callers: 1 (877) 474-9503 International callers: +1 (857) 244-7556 Passcode: 33730262 Webcast informati... 
 Printer Friendly Version
07/21/14Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
200 Patient Phase II Clinical Trial to Begin During Third Calendar Quarter of 2014 Second FDA Division Supports Expedited Development Path for AVP-786 ALISO VIEJO, Calif., July 21, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for a Phase II study assessing the safety and efficacy of AVP-786, Avanir's next generation compound. The company p... 
 Printer Friendly Version
07/16/14Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study
--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA® substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic condit... 
 Printer Friendly Version
06/30/14Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the Alzheimer's Association International Conference (AAIC)
ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela Center in Cope... 
 Printer Friendly Version
06/24/14Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment of Migraine at the American Headache Society Annual Meeting
ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered™ Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-P... 
 Printer Friendly Version
06/10/14Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine
--Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment-- ALISO VIEJO, Calif., June 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary efficacy ... 
 Printer Friendly Version
05/30/14Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June
ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul Burden of pseudobulbar affect (PBA) symptoms in veterans with traumatic... 
 Printer Friendly Version
05/28/14Avanir Pharmaceuticals to Participate in Two Conferences in June
ALISO VIEJO, Calif., May 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in June. Jefferies 2014 Global Healthcare Conference Presentation date: Tuesday, June 3, 2014 Presentation time: 3:30 p.m. E.T. The JMP Securities Healthcare Conference Presentation date: Tuesday, June 24, 2014 Presentation time: 10:00 a.m. E.T. ... 
 Printer Friendly Version
05/27/14Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease
ALISO VIEJO, Calif., May 27, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. "Final completion of enrollment in this study is an important milestone for Avanir as we explore the therapeutic utility of AVP-923, and later ... 
 Printer Friendly Version
05/06/14Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results
ALISO VIEJO, Calif., May 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. Quarterly Financial Highlights Total company net revenues of $26.9 million Net NUEDEXTA® sales of $24.4 million Cash, cash equivalents, and restricted investments of $56.5 million as of March 31, 2014. "We are extremely pleased with the recent outcome of the NUEDEXTA ANDA litigation," said Keith A. Kat... 
 Printer Friendly Version
05/01/14Avanir Pharmaceuticals to Participate in Two Conferences in May
ALISO VIEJO, Calif., May 1, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in May. Deutsche Bank 39th Annual Health Care Conference Presentation date: Thursday, May 8, 2014 Presentation time: 2:10 p.m. E.T. Bank of America Merrill Lynch 2014 Health Care Conference Presentation date: Tuesday, May 13, 2014 Presentation time: 1:00 p.m. P.T... 
 Printer Friendly Version
04/30/14Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026
ALISO VIEJO, Calif., April 30, 2014, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs') for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pse... 
 Printer Friendly Version
04/29/14Avanir Pharmaceuticals Announces Date of Fiscal 2014 Second Quarter Financial Results and Conference Call
ALISO VIEJO, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended March 31, 2014 after market close on Tuesday May 6, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day. Conference Call Information: Domestic callers: 1 (866) 318-8614 International callers: +1 (617) 399-5133 Passcode: 89833749 Webcast information:... 
 Printer Friendly Version
04/28/14Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology
New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission Results from Pivotal Phase III Trial of Investigational Migraine Therapy AVP-825 to be Featured in 'Data Blitz' Session US Neurology Publication Concludes that PBA is Often Overlooked or Misdiagnosed in Alzheimer's Disease (AD) and Dementia Patients ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, spec... 
 Printer Friendly Version
03/26/14Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
ALISO VIEJO, Calif., March 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) of AVP-825, its innovative Breath Powered™ investigational drug-device combination product for the acute treatment of migraine. As previously reported the company's 505(b)(2) NDA for AVP-825 includes data from one pivotal phase III clinical trial for the acute treatment of migrai... 
 Printer Friendly Version
03/20/14Avanir Pharmaceuticals Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivo
Data shows that dextromethorphan exerts antidepressant-like actions mediated at least in part through sigma-1 receptors ALISO VIEJO, Calif., March 20, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the potenti... 
 Printer Friendly Version
03/19/14Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors
ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience. Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a position he has held since January 2010. He has also served as a direct... 
 Printer Friendly Version
03/19/14Avanir Pharmaceuticals Presents Data from a Benchmark Study of PBA Symptoms in Veterans with Mild Traumatic Brain Injury
Majority of Responding Veterans Surveyed Report Having PBA Symptoms, Adding an Extra Burden to Managing Life Post-TBI ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury (TBI) conducted in collaboration with the Department of Veterans Affairs (VA) and Evidera. The study will be presente... 
 Printer Friendly Version
02/28/14Avanir Pharmaceuticals to Participate in Two Conferences in March
ALISO VIEJO, Calif., Feb. 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March. Cowen & Company 34th Annual Healthcare Conference Location: Boston Marriott Copley Place, Boston, MA Presentation date: Tuesday March 4, 2014 Presentation time: 10:40 a.m. E.T. 26th Annual ROTH Conference Location: Ritz-Carlton, Laguna Niguel, CA ... 
 Printer Friendly Version
02/07/14Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ALISO VIEJO, Calif., Feb. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new employees to purchase a total of 48,400 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4). (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LO... 
 Printer Friendly Version
02/05/14Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results
ALISO VIEJO, Calif., Feb. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights Total company net revenues of $26.7 million Gross and net NUEDEXTA® sales increased to $31.3 million and $23.3 million, respectively Cash, cash equivalents, and restricted investments of $46.5 million as of December ... 
 Printer Friendly Version
01/30/14Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migraine
ALISO VIEJO, Calif., Jan. 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its innovative Breath Powered™ investigational drug-device combination product for the acute treatment of migraine. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) The company's 505(b)(2) NDA for AVP-825 includes data from one pivotal phase II... 
 Printer Friendly Version
01/28/14Avanir Pharmaceuticals Announces Date of Fiscal 2014 First Quarter Financial Results and Conference Call
ALISO VIEJO, Calif., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended December 31, 2013 after market close on Wednesday February 5, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day. Conference Call Information: Domestic callers: 1 (866) 318-8611 International callers: +1 (617) 399-5130 Passcode: 19078797 Webcast in... 
 Printer Friendly Version
01/13/14Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
ALISO VIEJO, Calif., Jan. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the quarter-ended December 31, 2013, in anticipation of the company's attendance at the J.P. Morgan 32nd Annual Healthcare Conference. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Based on preliminary financial information (unaudited) for the quarter-ended December 31, 2013, Avanir estimates: Total gross rev... 
 Printer Friendly Version
01/10/14Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ALISO VIEJO, Calif., Jan. 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on January 7, 2014, the Company approved the grant of stock options to new employees to purchase a total of 249,800 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4). (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901L... 
 Printer Friendly Version
01/06/14Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
ALISO VIEJO, Calif., Jan. 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the J.P. Morgan 32nd Annual Healthcare Conference. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Location: Westin St. Francis Hotel, San Francisco, CA Presentation date: Wednesday January 15, 2014 Presentation time: 11:30 a.m. PT A live webcast and 30-day archive of these presentat... 
 Printer Friendly Version